Harry interviews Andrew A. Radin, co-founder and CEO of twoXAR, an Artificial Intelligence driven drug discovery startup that unifies disparate data to identify potential disease treatments.
In this episode Harry talks with Milind Kamkolkar, chief data officer at Sanofi, about how big pharma can start using new data sources to uncover new insights about disease.
Harry’s guest is Dr. Shrujal Baxi, medical director of Flatiron Health. On the agenda: how technology can help create the real-world evidence needed to achieve better patient outcomes and accelerate research into new areas.
Harry asks Dr. Ron Alfa, vice president of discovery and product at Recursion Pharmaceuticals, what efficiencies could be achieved and what problems could be solved if data science were applied to drug discovery.
Harry’s guest is Guido Lanza, president and CEO of Numerate. They tackle the question: What if the introduction of Artificial Intelligence into drug discovery allowed us to create a true learning loop?
Harry speaks with Wout Brusselaers, CEO and founder of Deep6.AI, about new technology that could help find patients for clinical trials in minutes rather than months.
To listen to the podcast via iTunes click here
At MoneyBall Medicine, host Harry Glorikian talks with leaders in the healthcare and life sciences industry about the ongoing data-driven transformation of their industry. Click here for more.